Investigational New Drugs

Publisher: Springer Publishing Company

Founded in: 1983

Total resources: 32

E-ISSN: 1573-0646

ISSN: 0167-6997

Subject: R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Investigational New Drugs

Menu

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

By King Constance,Diaz Henry,Barnard Darlene,Barda David,Clawson David,Blosser Wayne,Cox Karen,Guo Sherry,Marshall Mark in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 213-226

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

By Jeong Woondong,Park Sook,Rapisarda Annamaria,Fer Nicole,Kinders Robert,Chen Alice,Melillo Giovanni,Turkbey Baris,Steinberg Seth,Choyke Peter,Doroshow James,Kummar Shivaani in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 340-346

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis

By Jo Jae-Cheol,Hong Yong,Kim Kyu-Pyo,Lee Jae-Lyun,Lee Jeeyun,Park Young,Kim Sun,Ryu Jin-Sook,Lee Jong-Seok,Kim Tae in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 369-376

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

By Ganesan Prasanth,Piha-Paul Sarina,Naing Aung,Falchook Gerald,Wheler Jennifer,Fu Siqing,Hong David,Kurzrock Razelle,Janku Filip,Laday Shell,Bedikian Agop,Kies Merrill,Wolff Robert,Tsimberidou Apostolia in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 279-286

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

By Richter Suzanne,Bedard Philippe,Chen Eric,Clarke Blaise,Tran Ben,Hotte Sebastien,Stathis Anastasios,Hirte Hal,Razak Albiruni,Reedijk Michael,Chen Zhuo,Cohen Brenda,Zhang Wen-Jiang,Wang Lisa,Ivy S.,Moore Malcolm,Oza Amit,Siu Lillian,McWhirter Elaine in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 243-249

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

By Deming Dustin,Ninan Jacob,Bailey Howard,Kolesar Jill,Eickhoff Jens,Reid Joel,Ames Matthew,McGovern Renee,Alberti Dona,Marnocha Rebecca,Espinoza-Delgado Igor,Wright John,Wilding George,Schelman William in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 323-329

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John,McCall Shannon,Nixon Andrew,Brady John,Pang Herbert,Rushing Christel,Cohn Allen,Starodub Alexander,Arrowood Christy,Haley Sherri,Meadows Kellen,Morse Michael,Uronis Hope,Blobe Gerard,Hsu S.,Zafar S.,Hurwitz Herbert in (2014)

Investigational New Drugs , Vol. 32, Iss. 2, 2014-04 , pp. 330-339

Springer Publishing Company

Abstract Access to resources Recommend Favorite